Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi’s COVID Pill Hits Main Goal in PIII, Discussion on Regulatory Path to Follow
September 29, 2022
- Yakult Honsha Pulls NDA for Blood Cancer Med Duvelisib in Japan
September 29, 2022
- Taisho Files Autoinjector Version of RA Med Nanozora in Japan
September 29, 2022
- Maruishi/Kissei’s Pruritus Med Difelikefalin Filed in Japan
September 29, 2022
- Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
- Evusheld Can Fulfill Immunodeficient Patients’ Needs: AstraZeneca Japan VP
September 28, 2022
- Sumitomo Appeals to US Court to Overturn Dismissal of Latuda’s Use Patent
September 28, 2022
- Janssen’s CAR-T Therapy Carvykti Approved in Japan
September 27, 2022
- Promotions via In-Hospital Seminars, Webinars, Internet Channels Log Two-Digit Growth in August: Intage
September 27, 2022
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- Hospira Barred from Launching Lexiscan Generic until Oct. 5: Astellas
September 27, 2022
- Healios Licenses Non-Exclusive Rights for iPSC Line to RxCell
September 26, 2022
- Towa Prevails in IP High Court Ruling for Livalo Damage Suit, Kowa Mulls Next Step
September 22, 2022
- Pfizer Japan to Discontinue Ibrance’s Capsule Products
September 22, 2022
- Janssen Aims to Rank Among Top 3 Drug Makers in Japan by 2024: Local Chief
September 22, 2022
- UCB’s Epilepsy Drug Brivaracetam Hits PIII Goal, Japan Submission Eyed in 2023
September 21, 2022
- Otsuka’s Lupus Nephritis Med Lupkynis Wins European Greenlight
September 21, 2022
- Takeda’s CMV Drug Maribavir Snags EU Panel Backing
September 21, 2022
- Boehringer Ingelheim Revamping Biz Sites in Japan to Spur Communications among Drug Reps
September 20, 2022
- Daiichi Sankyo Apologizes for Arrest of Employee
September 20, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…